Full Press Release Details
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach.
CRSP
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
Key Takeaway: CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
Price reaction · baseline $55.53 (2024-05-07 close) · hit after-hours · 1 other CRSP headline(s) in the window, move may be shared
day 0 close · peak
-4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension